VC
CUE icon

Voss Capital’s Cue Biopharma CUE Stock Holding History

Voss Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,167
Closed -$446K – 51
2023
Q1 		$446K Hold
4,167
– – 0.06% 34
2022
Q4 		$356K Sell
4,167
-2,500
-37% -$229K 0.07% 39
2022
Q3 		$446K Buy
6,667
+3,334
+100% +$287K 0.13% 35
2022
Q2 		$249K Buy
+3,333
New +$390K 0.08% 34
2021
Q3 		– Sell
-4,167
Closed -$1.46M – 34
2021
Q2 		$1.46M Buy
4,167
+834
+25% +$323K 0.61% 28
2021
Q1 		$1.22M Sell
3,333
-4,024
-55% -$1.66M 0.51% 35
2020
Q4 		$2.76M Sell
7,357
-195
-3% -$77.9K 1.39% 25
2020
Q3 		$3.41M Buy
7,552
+6,125
+429% +$3.53M 1.95% 24
2020
Q2 		$1.05M Sell
1,427
-1,529
-52% -$1.11M 0.7% 28
2020
Q1 		$749K Sell
2,956
-127
-4% -$61.6K 1% 19
2019
Q4 		$1.47M Buy
+3,083
New +$968K 0.22% 63

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Voss Capital's CUE Position: Q2 2023 in Review

Voss Capital sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 4,167 shares — an estimated $446K sold.

Voss Capital first reported a position in CUE in Q4 2019 and held it in 11 quarters. The position peaked at $3.41M in Q3 2020. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Voss Capital reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Voss Capital sold 4,167 Cue Biopharma shares in Q2 2023, an estimated $446K.
  • Voss Capital first reported a position in Cue Biopharma in Q4 2019 and held it in 11 quarters.
  • Voss Capital's Cue Biopharma position peaked at $3.41M in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Voss Capital's 13F filing for Q2 2023, filed 28 Jul 2023.